<DOC>
	<DOC>NCT02531126</DOC>
	<brief_summary>The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.</brief_summary>
	<brief_title>Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis</brief_title>
	<detailed_description>The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Previous participation on a trial of RPC1063 for ulcerative colitis (UC) and may benefit from continued treatment Require initiation of other therapies used in the treatment of UC Pregnant, lactating, or have a positive serum pregnancy test Have clinically relevant cardiovascular conditions or other relevant disease that would put the patient at risk or make interpretation of the trial difficult</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>